Phase II study of brigatinib in ROS1 positive non-small cell lung cancer (NSCLC) patients previously treated with crizotinib: Barossa cohort 2.

Haruko Daga,Seiji Niho,Jun Sakakibara-Konishi,Hiroshi Tanaka,Yasushi Goto,Kadoaki Ohashi,Ryo Toyozawa,Masahiro Kodani,Toshiaki Takahashi,Yoshihiro Hattori,Masahiro Morise,Takaya Ikeda,Shingo Matsumoto,Kiyotaka Yoh,Shogo Nomura,Koichi Goto

Phase II study of brigatinib in ROS1 positive non-small cell lung cancer (NSCLC) patients previously treated with crizotinib: Barossa cohort 2.

2021

Haruko Daga
Seiji Niho
Jun Sakakibara-Konishi
Hiroshi Tanaka
Yasushi Goto
Kadoaki Ohashi
Ryo Toyozawa
Masahiro Kodani
Toshiaki Takahashi
Yoshihiro Hattori
Masahiro Morise
Takaya Ikeda
Shingo Matsumoto
Kiyotaka Yoh
Shogo Nomura
Koichi Goto

9040Background: Brigatinib is a next-generation tyrosine kinase inhibitor targeting ALK and ROS1. Crizotinib is the first drug approved for the treatment of ROS1 fusion-positive NSCLC. Standard tre...

Keywords:

Brigatinib
Cancer research
Medicine
ROS1
Tyrosine-kinase inhibitor
non-small cell lung cancer (NSCLC)
Cohort
Drug
Crizotinib
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations